In-vivo Tissue Uptake and Retention of Sn-117m(4+)DTPA in a Human Subject with Metastatic Bone Pain and in Normal Mice

An overwhelming amount of evidence demonstrates sex-induced variation in pain processing, and has thus increased the focus on sex as an essential parameter for optimization of in vivo models in pain research. Mammary cancer cells are often used to model metastatic bone pain in vivo, and are commonly used in both males and females. Here we demonstrate that compared to males, females have an increased capacity for recovery following inoculation of MRMT-1 mammary cells, thus potentially causing a sex-dependent bias of the progression of the pain state.

Download Full-text

Effect of sex in the MRMT-1 model of cancer-induced bone pain

F1000Research ◽

10.12688/f1000research.6827.2 ◽

2015 ◽

Vol 4 ◽

pp. 445

Author(s):

Sarah Falk ◽

Tamara Al-Dihaissy ◽

Laura Mezzanotte ◽

Anne-Marie Heegaard

Keyword(s):

Mammary Cancer ◽

Bone Pain ◽

Female Rats ◽

Male Rats ◽

Mammary Cells ◽

In Vivo Models ◽

Metastatic Bone Pain ◽

Essential Parameter ◽

Males And Females

An overwhelming amount of evidence demonstrates sex-induced variation in pain processing, and has thus increased the focus on sex as an essential parameter for optimization of in vivo models in pain research. Mammary cancer cells are often used to model metastatic bone pain in vivo, and are commonly used in both males and females. Here we demonstrate that compared to male rats, female rats have an increased capacity for recovery following inoculation of MRMT-1 mammary cells, thus potentially causing a sex-dependent bias in interpretation of the data.

Download Full-text

Effect of sex in the MRMT-1 model of cancer-induced bone pain

F1000Research ◽

10.12688/f1000research.6827.3 ◽

2015 ◽

Vol 4 ◽

pp. 445 ◽

Cited By ~ 4

Author(s):

Sarah Falk ◽

Tamara Al-Dihaissy ◽

Laura Mezzanotte ◽

Anne-Marie Heegaard

Keyword(s):

Mammary Cancer ◽

Bone Pain ◽

Female Rats ◽

Male Rats ◽

Mammary Cells ◽

In Vivo Models ◽

Metastatic Bone Pain ◽

Essential Parameter ◽

Males And Females

An overwhelming amount of evidence demonstrates sex-induced variation in pain processing, and has thus increased the focus on sex as an essential parameter for optimization of in vivo models in pain research. Mammary cancer cells are often used to model metastatic bone pain in vivo, and are commonly used in both males and females. Here we demonstrate that compared to male rats, female rats have an increased capacity for recovery following inoculation of MRMT-1 mammary cells, thus potentially causing a sex-dependent bias in interpretation of the data.

Download Full-text

Corydalis Saxicola Bunting Total Alkaloids Attenuate Walker 256-Induced Bone Pain and Osteoclastogenesis by Suppressing RANKL-Induced NF-κB and c-Fos/NFATc1 Pathways in Rats

Frontiers in Pharmacology ◽

10.3389/fphar.2020.609119 ◽

2021 ◽

Vol 11 ◽

Author(s):

Linjie Ju ◽

Peipei Hu ◽

Ping Chen ◽

Jiejie Wu ◽

Zhuoqun Li ◽

...

Keyword(s):

Bone Pain ◽

Bone Structure ◽

Osteolytic Lesion ◽

Bone Cancer ◽

Total Alkaloids ◽

Candidate Drug ◽

Metastatic Bone Pain ◽

Walker 256

Metastatic bone pain is characterized by insufferable bone pain and abnormal bone structure. A major goal of bone cancer treatment is to ameliorate osteolytic lesion induced by tumor cells. Corydalis saxicola Bunting total alkaloids (CSBTA), the alkaloid compounds extracted from the root of C. saxicola Bunting, have been shown to possess anticancer and analgesic properties. In this study, we aimed to verify whether CSBTA could relieve cancer induced bone pain and inhibit osteoclastogenesis. The in vivo results showed that CSBTA ameliorated Walker 256 induced bone pain and osteoporosis in rats. Histopathological changes also supported that CSBTA inhibited Walker 256 cell-mediated osteolysis. Further in vitro analysis confirmed that CSBTA reduced the expression of RANKL and downregulate the level of RANKL/OPG ratio in breast cancer cells. Moreover, CSBTA could inhibit osteoclastogenesis by suppressing RANKL-induced NF-κB and c-Fos/NFATc1 pathways. Collectively, this study demonstrated that CSBTA could attenuate cancer induced bone pain via a novel mechanism. Therefore, CSBTA might be a promising candidate drug for metastatic bone pain patients.

Download Full-text